analiza aiqbench
The REMEDI benchmark addresses a critical gap in machine unlearning by providing a realistic, multi-label evaluation framework specifically for clinical disease inference, moving beyond synthetic datasets to test methods against real-world safety constraints. Analysis of existing approaches reveals a significant trade-off between model utility and the extent of data removal, highlighting that current unlearning techniques are largely unsuited for complex medical classification tasks. This resource offers a necessary standard for researchers aiming to develop privacy-preserving AI systems that can effectively forget specific patient data without compromising diagnostic accuracy.
REMEDI: A Benchmark for Retention and Unlearning Evaluation in Multi-label Clinical Disease Inference
arXiv:2606.07141v1 Announce Type: new Abstract: Language models trained for clinical disease inference are trained on patient data, which may include sensitive and private information, and data owners may request the removal of their data from a trained model due to privacy or copyright concerns. However, exactly unlearning patient-specific data is intractable, and retraining with minor data removal is resource-intensive. While there exists several machine unlearning methods that can be used, their utility is generally restricted to non-medical domains. Moreover, the existing benchmarks for evaluating such unlearning methods primarily utilize synthetically curated datasets, which are not truly representative of real-world systems. Hence, the effectiveness of these unlearning methods in the medical domain is largely unclear. To this end, we introduce REMEDI, an extensive benchmark for machine unlearning tailored to multi-label and multiclass clinical disease inference, where label correlations, longitudinal structure, and safety constraints make unlearning particularly challenging. Unlike the existing benchmarks, REMEDI considers: (1) a relevant application domain (medical), (2) comprehensive unlearning setups involving diverse sets of forget instances, (3) challenging unlearning scenarios including multi-label and multi-class classification tasks, and (4) evaluation metrics involving performance both in terms of utility and extent of unlearning achieved. REMEDI is developed using the MIMIC-III clinical database that contains comprehensive clinical data of patients. Experiments with existing unlearning methods indicate that there exists a trade-off between utility and unlearning performance. They are also largely unsuited to multi-label classification tasks. To facilitate reproducibility, we make our benchmark publicly available.
Abstract:Language models trained for clinical disease inference are trained on patient data, which may include sensitive and private information, and data owners may request the removal of their data from a trained model due to privacy or copyright concerns. However, exactly unlearning patient-specific data is intractable, and retraining with minor data removal is resource-intensive. While there exists several machine unlearning methods that can be used, their utility is generally restricted to non-medical domains. Moreover, the existing benchmarks for evaluating such unlearning methods primarily utilize synthetically curated datasets, which are not truly representative of real-world systems. Hence, the effectiveness of these unlearning methods in the medical domain is largely unclear. To this end, we introduce REMEDI, an extensive benchmark for machine unlearning tailored to multi-label and multiclass clinical disease inference, where label correlations, longitudinal structure, and safety constraints make unlearning particularly challenging. Unlike the existing benchmarks, REMEDI considers: (1) a relevant application domain (medical), (2) comprehensive unlearning setups involving diverse sets of forget instances, (3) challenging unlearning scenarios including multi-label and multi-class classification tasks, and (4) evaluation metrics involving performance both in terms of utility and extent of unlearning achieved. REMEDI is developed using the MIMIC-III clinical database that contains comprehensive clinical data of patients. Experiments with existing unlearning methods indicate that there exists a trade-off between utility and unlearning performance. They are also largely unsuited to multi-label classification tasks. To facilitate reproducibility, we make our benchmark publicly available.
Machine Learning (cs.LG); Artificial Intelligence (cs.AI)
arXiv:2606.07141 [cs.LG]
(or arXiv:2606.07141v1 [cs.LG] for this version)
https://doi.org/10.48550/arXiv.2606.07141 Focus to learn more arXiv-issued DOI via DataCite (pending registration)
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.
Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.
Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Text integral sub licența deschisă a publicației · 335 cuvinte
Subiecte conexe
Amazon is investing in the Lean Focused Research Organization
Amazon Science · 26 iul. 2026

Amazon Research Awards recipients announced
Amazon Science · 27 mai 2026

34 Amazon Research Awards Build on Trainium recipients announced
Amazon Science · 5 aug. 2026

XtalPi Holdings Limited: XtalPi Holdings Announces 2026 Interim Results
finanznachrichten.de · 19 aug. 2026